Epithelial ovarian cancer remains among the most lethal gynecological malignancies worldwide, frequently presenting at advanced stages with peritoneal dissemination. While standard platinum-based chemotherapy initially achieves remission, recurrence and chemoresistance present persistent clinical challenges. Malignant cells adapt their energy production to sustain rapid proliferation, relying heavily on aerobic glycolysis. Consequently, researchers actively investigate metabolic interventions to disrupt these survival pathways. Recent studies emphasize targeted HK2 silencing as an effective mechanism to dismantle tumor bioenergetics. Utilizing advanced nanocarriers, targeted delivery platforms now allow precise molecular inhibition.

The Metabolic Burden of Aerobic Glycolysis in Malignant Ovarian Cells

Malignant cells reconfigure their metabolic architecture to survive within hypoxic and nutrient-deprived tumor microenvironments. In healthy tissues, cells rely primarily on mitochondrial oxidative phosphorylation to generate cellular energy. Conversely, aggressive ovarian cancer cells favor aerobic glycolysis, widely known as the Warburg effect. This metabolic shift accelerates glucose consumption and converts the majority of pyruvate into lactate, regardless of oxygen availability. Although glycolysis produces fewer adenosine triphosphate molecules per glucose unit, it generates energy rapidly. Furthermore, this pathway provides essential carbon intermediates required for accelerated nucleotide, protein, and lipid biosynthesis. Hexokinase 2 serves as the initial rate-limiting enzyme in this pathway. Specifically, HK2 phosphorylates intracellular glucose into glucose-6-phosphate, committing it to glycolytic breakdown. In addition, HK2 binds to outer mitochondrial membranes, directly suppressing apoptotic cascades. Elevated HK2 expression correlates with tumor progression, chemoresistance, and poor patient prognosis. Consequently, selective HK2 inhibition represents an attractive therapeutic approach to starve malignant cells. However, non-specific small-molecule inhibitors often cause systemic toxicity, necessitating advanced targeted delivery strategies.

Structural Innovation of Folate-Decorated Core-Shell Tecto-Dendrimers

Small interfering RNA offers tremendous potential to silence disease-driving oncogenes with profound sequence specificity. Nevertheless, unprotected siRNA degrades rapidly in systemic circulation due to endogenous serum nucleases. Moreover, strong negative electrostatic charges prevent naked siRNA from crossing cell membranes efficiently. To overcome these pharmacological barriers, scientists engineered a folate-functionalized core-shell tecto-dendrimer platform, termed FA-G5/G3. This macromolecular carrier combines a generation 5 polyamidoamine core with outer generation 3 dendrimer shells. Consequently, the nanostructure exhibits a stable spherical architecture, uniform hydrodynamic size, and excellent biocompatibility. Researchers covalently conjugated folic acid molecules onto the exterior dendrimer surface to exploit tumor-specific surface markers. Epithelial ovarian carcinoma cells markedly overexpress folate receptor alpha compared to normal tissues. Therefore, these folate ligands direct the nanocomplex selectively toward malignant cells while sparing healthy organs. Additionally, cationic dendrimer branches electrostatically compress anionic HK2 siRNA into compact nanoparticles, shielding the genetic payload from enzymatic degradation. Thus, this engineered tecto-dendrimer provides a robust vehicle for targeted oncological gene delivery.

Mechanisms of Targeted HK2 Silencing and Downstream Effects

The therapeutic efficacy of the FA-G5/G3 nanoplatform depends on efficient cellular uptake and subsequent cytosolic payload release. Upon reaching target ovarian cancer cells, the nanocomplex binds selectively to surface folate receptors. Subsequently, receptor-mediated endocytosis internalizes the intact nanoparticle into endosomal compartments. Inside the endosomes, the tertiary amines of the dendrimer core elicit a potent proton sponge effect. This influx triggers osmotic endosomal rupture, safely releasing the siRNA into the cytoplasm. Once in the cytosol, the siRNA engages the RNA-induced silencing complex to degrade target HK2 transcripts. Consequently, successful targeted HK2 silencing substantially diminishes hexokinase 2 protein levels. This enzymatic disruption directly halts the initial commitment step of glycolytic flux. Furthermore, the downstream metabolic cascade markedly decreases lactate dehydrogenase A expression. Because cells cannot efficiently convert pyruvate to lactate, extracellular lactate accumulation declines dramatically. Ultimately, this metabolic blockade deprives ovarian cancer cells of essential adenosine triphosphate, inducing growth arrest and triggering apoptosis.

Overcoming siRNA Delivery Barriers with Nanoscale Precision

Systemic delivery of therapeutic RNA has historically encountered major hurdles, including rapid renal filtration and immunogenic responses. Traditional liposomal and linear polymer systems often suffer from structural instability and non-specific biodistribution. In contrast, core-shell tecto-dendrimers provide distinct structural advantages that solve these clinical translation bottlenecks. Their highly branched architecture ensures monodisperse particle size and predictable surface chemistry. Furthermore, the outer dendrimer shells create steric shielding that prevents non-specific protein adsorption and macrophage clearance. This protection prolongs intravascular circulation, facilitating enhanced accumulation at tumor sites. Additionally, multivalent folate functionalization promotes high-affinity binding to ovarian cancer cells without generating excessive carrier-mediated cytotoxicity. In vitro assays confirm that the empty dendrimer vehicle preserves cell viability across therapeutic concentrations. Meanwhile, the siRNA-loaded tecto-dendrimers induce profound gene knockdown at lower systemic dosages. Therefore, the nanocomplex achieves precise target silencing while maintaining a favorable safety profile. Consequently, this platform establishes a versatile paradigm for delivering diverse therapeutic nucleic acids in precision oncology.

Translational Implications for Ovarian Cancer Therapeutics

Targeting cancer cell metabolism provides a compelling strategy to overcome therapeutic resistance in ovarian oncology. Standard clinical protocols relying on platinum compounds and taxanes frequently fail over time due to adaptive resistance mechanisms. By extinguishing aerobic glycolysis, HK2 silencing deprives ovarian cancer cells of the metabolic plasticity required to survive cytotoxic stress. Furthermore, reducing extracellular lactate production normalizes the acidic tumor microenvironment. Because an acidic microenvironment suppresses antitumor immunity, decreasing lactate output can restore the cytotoxic activity of local immune cells. In the Indian clinical landscape, where advanced-stage ovarian cancer presentations remain prevalent, metabolically targeted therapies offer promising adjuvant options. Future translational research must explore combining folate-targeted HK2 nanotherapeutics with standard chemotherapy or immune checkpoint inhibitors. Although moving this platform into clinical trials requires comprehensive in vivo pharmacokinetic validation, these findings highlight a powerful nanotechnological approach. Ultimately, metabolic reprogramming through targeted gene silencing could significantly refine individualized ovarian cancer management.

Frequently Asked Questions

Why is HK2 considered a crucial metabolic target in ovarian cancer?

Hexokinase 2 catalyzes the first committed step of glycolysis by converting glucose into glucose-6-phosphate. In ovarian cancer, malignant cells overexpress HK2 to accelerate energy generation and synthesize vital biomolecules through aerobic glycolysis. HK2 also attaches directly to mitochondrial membranes, preventing apoptotic cell death. Consequently, silencing HK2 disrupts tumor bioenergetics, reduces lactate production, and restores apoptotic signaling, rendering cancer cells vulnerable to destruction.

How do core-shell tecto-dendrimers improve siRNA delivery in cancer therapy?

Core-shell tecto-dendrimers overcome critical delivery obstacles by protecting vulnerable siRNA from enzymatic degradation and enabling targeted cellular entry. Their branched polymeric structure condenses negatively charged siRNA into stable nanostructures. Furthermore, surface folic acid ligands selectively direct the nanoparticles to receptor-overexpressing tumor cells. Upon cellular internalization, the dendrimer core induces endosomal escape through a proton sponge effect, safely releasing intact siRNA into the cytoplasm to achieve gene knockdown.

What is the clinical significance of folate receptor targeting in ovarian cancer?

Folate receptor alpha exhibits high overexpression across most epithelial ovarian carcinomas, while showing minimal presence in healthy adult tissues. Decorating therapeutic nanocarriers with folic acid ensures selective binding and receptor-mediated uptake into malignant cells. This precision targeting enhances local drug accumulation within the tumor bed while sparing normal physiological organs from toxicity. Consequently, folate-functionalized nanomedicines offer improved therapeutic indices and reduced adverse effects in advanced ovarian cancer care.

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or clinical guidance and should not substitute professional healthcare judgment. Healthcare professionals must exercise independent clinical discretion when evaluating diagnostic and treatment options. Refer to the latest local and national guidelines for clinical practice.

References

1. Wang X et al. Targeted HK2 Silencing via Folate-Decorated Core-Shell Tecto-Dendrimers Modulates Glycolysis-Associated Metabolic Processes in Ovarian Cancer Cells. Macromol Rapid Commun. 2026 Oct 25. doi: undefined. PMID: 42927644.
2. Zhang W, et al. Research progress on the mechanism of glycolysis in ovarian cancer. Front Immunol. 2023;14:1284853.
3. Lisboa-Filho CG, et al. The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors. Int J Mol Sci. 2023;24(24):17531.